Anthem Bioscienc Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Q4 FY26 earnings call analysis: revenue, margin, capex, fundraise and order book outlook from management commentary.

Published 24 May 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹50.1K Cr

Anthem Biosciences aims to maintain a revenue growth rate of around 20%, consistent with its historical performance over the past decade. Anthem Biosciences aims to maintain historical revenue growth of around 20% annually over the medium to long term.

From Anthem Bioscienc's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Price

₹871

Market Cap

₹50.1K Cr

P/E Ratio

84.5

How does Anthem Bioscienc rank in Pharmaceuticals & Biotechnology?

Compare Anthem Bioscienc against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Anthem Bioscienc — Quarterly revenue & net profit

Revenue Net Profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹611 Cr, net profit ₹190 Cr.

Full financials →

📊 Revenue & Sales Performance

→Anthem Biosciences aims to maintain a revenue growth rate of around 20%, consistent with its historical performance over the past decade.
→The company aspires to continue delivering around 20% growth in EBITDA and PAT alongside revenue growth.
→Recent revenue growth was about 15% due to market adjustments, but EBITDA and PAT grew over 30%.
→The launch of four new commercial molecules contributes around 8-9% to current revenues, with ramp-up expected over 2-3 years.
→Capacity expansions, especially Unit 4 (doubling custom synthesis and increasing fermentation capacity by 50%), position the company for future growth.
→The company anticipates broadening relationships with big pharma, expecting growth through new programs and acquisitions of biotech firms.
→Specialty ingredients segment targets ~20% growth.
→Restocking after destocking should positively impact top-line growth going forward.

📈 Profitability & Margins

→Anthem Biosciences aims to maintain historical revenue growth of around 20% annually over the medium to long term.
→EBITDA margins are expected to remain stable around 38-40%, leveraging operating leverage and backward integration gains.
→PAT growth has been strong (31% YoY in FY26), with aspirations to sustain similar trajectories supported by margin stability.
→The ramp-up of recently commercialized molecules is expected to take 2-3 years, contributing around 8-9% of current revenues, signaling future earnings growth.
→Major capex investments (Rs. 700 crores in FY27 and Rs. 500 crores thereafter) in Unit 4 expansion aim to substantially increase capacity and support growth.
→Inorganic growth through acquisitions is being explored but will be undertaken only if quality and strategic fit are met.
→The company expects further growth from increasing biotech funding, new client additions (including big pharma), and technology-driven service enhancements.
→No specific forward-looking EPS guidance was provided, but overall outlook is positive with a focus on sustaining growth and profitability.

See what Anthem Bioscienc said on profitability & margins — free account, 30 seconds.

🏗️ Capital Expenditure Plans

→Major ongoing capex is for Unit 4, Anthem's largest project, spanning 30 acres.
→Phase 1 investment of approx. Rs. 1,200 crores over FY27 and FY28, aiming for completion by March 2028.
→Phase 1 will nearly double custom synthesis capacity (adding 365 kiloliters) and increase fermentation capacity by 50% (adding 100 kiloliters).
→Unit 2 and Unit 3 expansions are ongoing (currently in CWIP).
→Post Phase 1, two more phases planned for Unit 4 to further double or triple overall capacity.
→FY27 capex expected around Rs. 700 crores; subsequent year around Rs. 500 crores.
→Focus is on becoming future-ready with increased agility, technology investments, including automation, continuous processing, and green chemistry.
→Open to inorganic growth through acquisitions but only when the right strategic fit is identified.

💰 Fundraising & Capital Structure

→No specific mention of any current or planned fundraising through debt or equity was made in the document.
→Company is focusing on large capex investments, particularly Unit 4 expansion, funded through internal cash flows as indicated by mention of flexible cash situation.
→Ajay Bhardwaj and Gawir Baig highlighted confidence in existing cash position enabling flexibility for potential acquisitions but no definite plans announced.
→Emphasis is on organic growth and selective inorganic acquisition only if the right opportunity arises; no immediate fundraising tied to these.
→Overall, no explicit indication of upcoming equity or debt fundraising in the near term.

See what Anthem Bioscienc said on fundraising & capital structure — free account, 30 seconds.

📋 Order Book & Pipeline

→Specialty Ingredients segment operates as a flow business without a traditional order book; products are manufactured and sold continuously to multiple customers across regions.
→For the CDMO business, order books exist primarily with commercial molecule customers who provide significant lead times, typically up to six months.
→No specific numeric details on overall pending orders or order book size are provided.
→The company has around 100 projects in early stages (discovery, development, optimization), with capacity to handle up to 200 projects without constraints.
→Expansion via Unit 3 and upcoming Unit 4 will increase capacity, supporting future order inflow.
→No near-term guidance on total order book was shared, but management emphasized strong demand and customer trust.
→Specialty Ingredients order momentum recovered with 8% growth in the latest quarter, and further growth expected with dedicated facilities planned.

Key Metrics

How does Anthem Bioscienc rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Anthem Bioscienc

See full Pharmaceuticals & Biotechnology sector rankings

What ANTHEM's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Torrent Pharmaceuticals Ltd (Q4 FY26)
Consolidated revenue for Q4 FY26 up 42%, EBITDA up 41%, margins stable at ~32% (Page 2). Key concall takeaways from Torrent Pharma.'s Q4 FY26 earnings call…
Kwality Pharmaceuticals Ltd (Q4 FY26)
FY26: Achieved INR503 crores revenue; oncology contributed INR100-120 crores. Key concall takeaways from Kwality Pharmaceuticals Ltd's Q4 FY26 earnings call…
RPG Life Sciences Ltd (Q4 FY26)
Domestic formulation growth driven by strong volume expansion (~9.8% volume growth in Q4 FY26 vs 1.1% industry) and new product launches (5.1% growth vs 2%…
SAIPARENT (Q4 FY26)
Long-term growth supported by over 50% revenue from long-term CDs contracts in regulated markets. Key concall takeaways from Sai Parenteral's's Q4 FY26…

Compare:vs SUNPHARMA vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Anthem Bioscienc Q4 FY26 results?

What is Anthem Bioscienc share price analysis?

Anthem Bioscienc currently shows a neutral. The stock trades at a P/E of 84.5 with a market cap of ₹50,132 Cr. Investors should review the full earnings analysis for detailed insights.

Is Anthem Bioscienc planning capital expenditure?

Major ongoing capex is for Unit 4, Anthem's largest project, spanning 30 acres. - Phase 1 investment of approx.

Keep Anthem Bioscienc on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.